206 related articles for article (PubMed ID: 30549211)
1. Pharmacogenetics and prediction of adverse events in prescription opioid use disorder patients.
Muriel J; Margarit C; Barrachina J; Ballester P; Flor A; Morales D; Horga JF; Fernández E; Peiró AM
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):439-448. PubMed ID: 30549211
[TBL] [Abstract][Full Text] [Related]
2. OPRM1 influence on and effectiveness of an individualized treatment plan for prescription opioid use disorder patients.
Muriel J; Margarit C; Planelles B; Serralta MJ; Puga C; Inda MD; Cutillas E; Morales D; Horga JF; Peiró AM
Ann N Y Acad Sci; 2018 Aug; 1425(1):82-93. PubMed ID: 29781244
[TBL] [Abstract][Full Text] [Related]
3. Long-term deprescription in chronic pain and opioid use disorder patients: Pharmacogenetic and sex differences.
Muriel J; Escorial M; Margarit C; Barrachina J; Carvajal C; Morales D; Peiró AM
Acta Pharm; 2023 Jun; 73(2):227-241. PubMed ID: 37307374
[TBL] [Abstract][Full Text] [Related]
4. Clinical prediction of opioid use disorder in chronic pain patients: a cohort-retrospective study with a pharmacogenetic approach.
Escorial M; Muriel J; Agulló L; Zandonai T; Margarit C; Morales D; Peiró AM
Minerva Anestesiol; 2024 May; 90(5):386-396. PubMed ID: 38619184
[TBL] [Abstract][Full Text] [Related]
5. OPRM1 Gene Interaction with Sleep in Chronic Pain Patients Treated with Opioids.
Margarit C; Ballester P; Inda MD; Roca R; Gomez L; Planelles B; Ajo R; Morales D; Peiro AM
Pain Physician; 2019 Jan; 22(1):97-107. PubMed ID: 30700073
[TBL] [Abstract][Full Text] [Related]
6. Gender based differences, pharmacogenetics and adverse events in chronic pain management.
Planelles B; Margarit C; Inda MD; Ballester P; Muriel J; Barrachina J; Ajo R; Esteban MD; Peiró AM
Pharmacogenomics J; 2020 Apr; 20(2):320-328. PubMed ID: 31745220
[TBL] [Abstract][Full Text] [Related]
7. Sex Bias and Genotype Influence on Opioid Safety Profile in Chronic Low Back Pain.
Margarit C; Roca R; Inda MD; Muriel J; Ballester P; Flor A; Morales D; Peiró AM
Clin J Pain; 2020 Jun; 36(6):420-429. PubMed ID: 32149782
[TBL] [Abstract][Full Text] [Related]
8. Genetic Contribution in Low Back Pain: A Prospective Genetic Association Study.
Margarit C; Roca R; Inda MD; Muriel J; Ballester P; Moreu R; Conte AL; Nuñez A; Morales D; Peiró AM
Pain Pract; 2019 Nov; 19(8):836-847. PubMed ID: 31269327
[TBL] [Abstract][Full Text] [Related]
9. The role of hydromorphone and OPRM1 in postoperative pain relief with hydrocodone.
Boswell MV; Stauble ME; Loyd GE; Langman L; Ramey-Hartung B; Baumgartner RN; Tucker WW; Jortani SA
Pain Physician; 2013; 16(3):E227-35. PubMed ID: 23703421
[TBL] [Abstract][Full Text] [Related]
10. Opioid-related genetic polymorphisms do not influence postoperative opioid requirement: A prospective observational study.
Aubrun F; Zahr N; Langeron O; Boccheciampe N; Cozic N; Belin L; Hulot JS; Khiami F; Riou B
Eur J Anaesthesiol; 2018 Jul; 35(7):496-504. PubMed ID: 29474345
[TBL] [Abstract][Full Text] [Related]
11. Gene polymorphisms of OPRM1 A118G and ABCB1 C3435T may influence opioid requirements in Chinese patients with cancer pain.
Gong XD; Wang JY; Liu F; Yuan HH; Zhang WY; Guo YH; Jiang B
Asian Pac J Cancer Prev; 2013; 14(5):2937-43. PubMed ID: 23803057
[TBL] [Abstract][Full Text] [Related]
12. [A pharmacogenetic analysis of dopaminergic and opioidergic genes in opioid addicts treated with the combination of naltrexone and guanfacine].
Kibitov АО; Krupitsky ЕМ; Blokhina ЕА; Verbitskaya ЕV; Brodyansky VМ; Alekseeva NP; Bushara NМ; Yaroslavtseva ТS; Palatkin VY; Masalov DV; Burakov АМ; Romanova ТN; Sulimov GY; Grinenko AY; Kosten Т; Nielsen D; Zvartau EE
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(11. Vyp. 2):36-48. PubMed ID: 28300812
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics of OPRM1.
Crist RC; Berrettini WH
Pharmacol Biochem Behav; 2014 Aug; 123():25-33. PubMed ID: 24201053
[TBL] [Abstract][Full Text] [Related]
14. Review of Opioid Pharmacogenetics and Considerations for Pain Management.
Owusu Obeng A; Hamadeh I; Smith M
Pharmacotherapy; 2017 Sep; 37(9):1105-1121. PubMed ID: 28699646
[TBL] [Abstract][Full Text] [Related]
15. Fundamental Considerations for Genetically-Guided Pain Management with Opioids Based on CYP2D6 and OPRM1 Polymorphisms.
Ruano G; Kost JA
Pain Physician; 2018 Nov; 21(6):E611-E621. PubMed ID: 30508992
[TBL] [Abstract][Full Text] [Related]
16. Withdrawal symptoms predict prescription opioid dependence in chronic pain patients.
Coloma-Carmona A; Carballo JL; Rodríguez-Marín J; Pérez-Carbonell A
Drug Alcohol Depend; 2019 Feb; 195():27-32. PubMed ID: 30562677
[TBL] [Abstract][Full Text] [Related]
17. Impact of CYP2D6 genotype on opioid use disorder deprescription: an observational prospective study in chronic pain with sex-differences.
Muriel J; Barrachina J; Del Barco G; Carvajal C; Escorial M; Margarit C; Ballester P; Peiró AM
Front Pharmacol; 2023; 14():1200430. PubMed ID: 37324467
[No Abstract] [Full Text] [Related]
18. Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene.
Reyes-Gibby CC; Shete S; Rakvåg T; Bhat SV; Skorpen F; Bruera E; Kaasa S; Klepstad P
Pain; 2007 Jul; 130(1-2):25-30. PubMed ID: 17156920
[TBL] [Abstract][Full Text] [Related]
19. Individual variability in clinical effect and tolerability of opioid analgesics - Importance of drug interactions and pharmacogenetics.
Solhaug V; Molden E
Scand J Pain; 2017 Oct; 17():193-200. PubMed ID: 29054049
[TBL] [Abstract][Full Text] [Related]
20. OPRM1 and COMT Gene-Gene Interaction Is Associated With Postoperative Pain and Opioid Consumption After Orthopedic Trauma.
Khalil H; Sereika SM; Dai F; Alexander S; Conley Y; Gruen G; Meng L; Siska P; Tarkin I; Henker R
Biol Res Nurs; 2017 Mar; 19(2):170-179. PubMed ID: 27903758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
